Table 1.

Venous thromboembolism in acute leukemia.

No. of patientsVenous thromboembolism(%)
AuthorStudy populationAML*APLALLAML*APLALL
*AML, excluding APL 
†Observation extends over long duration even after complete remission. 
‡PARKAA study group (Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase) 
Abbreviations: AML, acute myelogenous leukemia; APL, acute promyelocytic leukemia; ALL, acute lymphocytic leukemia 
Mohren et al 20062  455 340 7 108 10.8† 42.8† 13.0† 
Ziegler et al 20054  719 485 49 185 1.6 6.1 2.2 
DeStefano et al 20053  379 279 31 69 1.7 8.4 10.6 
Mitchell et al 20036  67‡   69   36.7 
No. of patientsVenous thromboembolism(%)
AuthorStudy populationAML*APLALLAML*APLALL
*AML, excluding APL 
†Observation extends over long duration even after complete remission. 
‡PARKAA study group (Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase) 
Abbreviations: AML, acute myelogenous leukemia; APL, acute promyelocytic leukemia; ALL, acute lymphocytic leukemia 
Mohren et al 20062  455 340 7 108 10.8† 42.8† 13.0† 
Ziegler et al 20054  719 485 49 185 1.6 6.1 2.2 
DeStefano et al 20053  379 279 31 69 1.7 8.4 10.6 
Mitchell et al 20036  67‡   69   36.7 
View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal